Nogo-receptor 1 deficiency has no influence on immune cell repertoire or function during experimental autoimmune encephalomyelitis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Litwak, Sara A ^a   Payne, Natalie L ^a   Campanale, Naomi ^a   Ozturk, Ezgi ^a   Lee, Jae Young ^a   Petratos, Steven ^b   Siatskas, Christopher ^a   Bakhuraysah, Maha ^a   Bernard, Claude C A ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NOGO 66 RECEPTOR; NOGO 66 RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; B LYMPHOCYTE; BLOOD CELL; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DEMYELINATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; LEUKOCYTE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; SPINAL CORD;

ANIMALS; B-LYMPHOCYTES; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GPI-LINKED PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; MYELIN PROTEINS; RECEPTORS, CELL SURFACE;

EID: 84891923979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082101     Document Type: Article

References (54)

1. Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12: 295-302. (Pubitemid 29378163)
2. McQualter JL, Bernard CC (2007) Multiple sclerosis: a battle between destruction and repair. J Neurochem 100: 295-306. (Pubitemid 46010991)
3. Baranzini SE, Nickles D (2012) Genetics of multiple sclerosis: swimming in an ocean of data. Curr Opin Neurol 25: 239-245.
4. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE (2012) The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 248: 87-103.
5. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, et al. (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18: 767-778.
6. Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139-145.
7. Wang D, Ayers MM, Catmull DV, Hazelwood LJ, Bernard CC, et al. (2005) Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia 51: 235-240. (Pubitemid 41297430)
8. Dutta R, Trapp BD (2007) Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68: S22-31; discussion S43-54. (Pubitemid 46848608)
9. Petratos S, Azari MF, Ozturk E, Papadopoulos R, Bernard CC (2010) Novel therapeutic targets for axonal degeneration in multiple sclerosis. J Neuropathol Exp Neurol 69: 323-334.
10. Schwab JM, Bernard F, Moreau-Fauvarque C, Chedotal A (2005) Injury reactive myelin/oligodendrocyte-derived axon growth inhibition in the adult mammalian central nervous system. Brain Res Brain Res Rev 49: 295-299. (Pubitemid 41160397)
11. Domeniconi M, Filbin MT (2005) Overcoming inhibitors in myelin to promote axonal regeneration. J Neurol Sci 233: 43-47. (Pubitemid 40804814)
12. Akbik F, Cafferty WB, Strittmatter SM (2012) Myelin associated inhibitors: a link between injury-induced and experience-dependent plasticity. Exp Neurol 235: 43-52.
13. Fournier AE, GrandPre T, Strittmatter SM (2001) Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409: 341-346. (Pubitemid 32151238)
14. Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, et al. (2002) Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci 22: 5505-5515. (Pubitemid 35386472)
15. Schwab ME (2010) Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci 11: 799-811.
16. Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, et al. (2004) The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 7: 736-744. (Pubitemid 38859058)
17. Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, et al. (2012) Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain 135: 1794-1818.
18. Yang Y, Liu Y, Wei P, Peng H, Winger R, et al. (2010) Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol 67: 498-507.
19. Fournier AE, Gould GC, Liu BP, Strittmatter SM (2002) Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci 22: 8876-8883. (Pubitemid 35379057)
20. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, et al. (2007) LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13: 1228-1233. (Pubitemid 47530642)
21. Satoh J, Onoue H, Arima K, Yamamura T (2005) Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis. J Neuropathol Exp Neurol 64: 129-138. (Pubitemid 40349311)
22. Satoh J, Tabunoki H, Yamamura T, Arima K, Konno H (2007) TROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesions. Neuropathol Appl Neurobiol 33: 99-107. (Pubitemid 46090314)
23. Theotokis P, Lourbopoulos A, Touloumi O, Lagoudaki R, Kofidou E, et al. (2012) Time course and spatial profile of Nogo-A expression in experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuropathol Exp Neurol 71: 907-920.
24. Pool M, Niino M, Rambaldi I, Robson K, Bar-Or A, et al. (2009) Myelin regulates immune cell adhesion and motility. Exp Neurol 217: 371-377.
25. Fry EJ, Ho C, David S (2007) A role for Nogo receptor in macrophage clearance from injured peripheral nerve. Neuron 53: 649-662. (Pubitemid 46283376)
26. McDonald CL, Steinbach K, Kern F, Schweigreiter R, Martin R, et al. (2011) Nogo receptor is involved in the adhesion of dendritic cells to myelin. J Neuroinflammation 8: 113.
27. Slavin A, Ewing C, Liu J, Ichikawa M, Slavin J, et al. (1998) Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 28: 109-120. (Pubitemid 28499584)
28. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, et al. (2010) B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 68: 369-383.
29. Kim JE, Liu BP, Park JH, Strittmatter SM (2004) Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 44: 439-451. (Pubitemid 39423346)
30. Barnard AL, Chidgey AP, Bernard CC, Boyd RL (2009) Androgen depletion increases the efficacy of bone marrow transplantation in ameliorating experimental autoimmune encephalomyelitis. Blood 113: 204-213.
31. Short MA, Campanale N, Litwak S, Bernard CC (2011) Quantitative and phenotypic analysis of bone marrow-derived cells in the intact and inflamed central nervous system. Cell Adh Migr 5: 373-381.
32. Skokowa J, Klimiankou M, Klimenkova O, Lan D, Gupta K, et al. (2012) Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. Nat Med 18: 1550-1559.
33. Payne NL, Sun G, Herszfeld D, Tat-Goh PA, Verma PJ, et al. (2012) Comparative study on the therapeutic potential of neurally differentiated stem cells in a mouse model of multiple sclerosis. PLoS One 7: e35093.
34. McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, et al. (2001) Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 194: 873-882.
35. Okuda Y, Okuda M, Bernard CC (2002) The suppression of T cell apoptosis influences the severity of disease during the chronic phase but not the recovery from the acute phase of experimental autoimmune encephalomyelitis in mice. J Neuroimmunol 131: 115-125.
36. Payne NL, Sun G, McDonald C, Moussa L, Emerson-Webber A, et al. (2013) Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain Behav Immun 30: 103-114.
37. David S, Fry EJ, Lopez-Vales R (2008) Novel roles for Nogo receptor in inflammation and disease. Trends Neurosci 31: 221-226.
38. Zhang L, Zheng S, Wu H, Wu Y, Liu S, et al. (2009) Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. J Neurosci 29: 6348-6352.
39. Slavin AJ, Soos JM, Stuve O, Patarroyo JC, Weiner HL, et al. (2001) Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. J Clin Invest 108: 1133-1139. (Pubitemid 32995371)
40. von Budingen HC, Bar-Or A, Zamvil SS (2011) B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 23: 713-720.
41. Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, et al. (1997) Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med (Berl) 75: 77-88. (Pubitemid 27119487)
42. Teng FY, Tang BL (2005) Nogo signaling and non-physical injury-induced nervous system pathology. J Neurosci Res 79: 273-278. (Pubitemid 40278340)
43. Fontoura P, Ho PP, DeVoss J, Zheng B, Lee BJ, et al. (2004) Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol 173: 6981-6992. (Pubitemid 39541087)
44. Constant S, Schweitzer N, West J, Ranney P, Bottomly K (1995) B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol 155: 3734-3741.
45. Kennel De March A, De Bouwerie M, Kolopp-Sarda MN, Faure GC, Bene MC, et al. (2003) Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis. J Neuroimmunol 135: 117-125. (Pubitemid 36170158)
46. Lyons JA, San M, Happ MP, Cross AH (1999) B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 29: 3432-3439. (Pubitemid 29527790)
47. Steinbach K, McDonald CL, Reindl M, Schweigreiter R, Bandtlow C, et al. (2011) Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis. PLoS One 6: e26341.
48. Zheng B, Atwal J, Ho C, Case L, He XL, et al. (2005) Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad Sci U S A 102: 1205-1210. (Pubitemid 40170750)
49. Teuscher C, Bunn JY, Fillmore PD, Butterfield RJ, Zachary JF, et al. (2004) Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis. Am J Pathol 165: 1593-1602. (Pubitemid 39435158)
50. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E (2013) Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 8: e66308.
51. Ponomarev ED, Shriver LP, Maresz K, Dittel BN (2005) Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81: 374-389. (Pubitemid 41359292)
52. Flugel A, Bradl M (2001) New tools to trace populations of inflammatory cells in the CNS. Glia 36: 125-136. (Pubitemid 33055901)
53. Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201: 647-657. (Pubitemid 40289554)
54. Yan J, Zhou X, Guo JJ, Mao L, Wang YJ, et al. (2012) Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J Neurochem 120: 721-731.